Tricida Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 55

Employees

  • Stock Symbol
  • 1T7

Stock Symbol

  • Share Price
  • $0.10
  • (As of Monday Closing)

Tricida General Information

Description

Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

Contact Information

Website
www.tricida.com
Formerly Known As
Trilypsa
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2108 North Street
  • Suite 4935
  • Sacramento, CA 95816
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STU
Vertical(s)
Corporate Office
  • 2108 North Street
  • Suite 4935
  • Sacramento, CA 95816
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tricida Stock Performance

As of 23-Jan-2023, Tricida’s stock price is $0.10. Its current market cap is $6.27M with 58M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.10 $0.12 $0.10 - $13.52 $6.27M 58M 4.63K -$2.37

Tricida Financials Summary

As of 30-Sep-2022, Tricida has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 686,486 503,955 243,586 1,584,705
Revenue 0 0 0 0
EBITDA (116,488) (159,022) (249,887) (170,404)
Net Income (133,912) (176,566) (264,791) (176,813)
Total Assets 93,879 168,506 351,685 371,826
Total Debt 207,995 141,544 210,433 68,229
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tricida Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tricida‘s full profile, request access.

Request a free trial

Tricida Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Tricida‘s full profile, request access.

Request a free trial

Tricida Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverime
Drug Discovery
Sacramento, CA
55 As of 2023

San Diego, CA

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tricida Competitors (33)

One of Tricida’s 33 competitors is Nascent Biotech, a Corporation company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nascent Biotech Corporation San Diego, CA
Akebia Therapeutics Formerly VC-backed Cambridge, MA
Resverlogix Corporation Calgary, Canada
Esperion Therapeutics Private Equity-Backed Ann Arbor, MI
Ayala Pharmaceuticals Corporation Wilmington, DE
You’re viewing 5 of 33 competitors. Get the full list »

Tricida Patents

Tricida Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023064357-A1 Pharmaceutical compositions for the treatment of lithiasis disorders Inactive 13-Oct-2021
JP-2024512296-A Crosslinked poly(allylamine) polymer pharmaceutical composition Active 01-Mar-2021
JP-2026102594-A Crosslinked poly(allylamine) polymer pharmaceutical composition Pending 01-Mar-2021
AU-2021431510-A1 Crosslinked poly(allylamine) polymer pharmaceutical compositions Pending 01-Mar-2021
JP-7828096-B2 Crosslinked poly(allylamine) polymer pharmaceutical compositions Active 01-Mar-2021 C08F226/02
To view Tricida’s complete patent history, request access »

Tricida Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tricida Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tricida‘s full profile, request access.

Request a free trial

Tricida ESG

Risk Overview

Risk Rating

Updated April, 30, 2023

40.26 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

To view Tricida’s complete esg history, request access »

Tricida FAQs

  • When was Tricida founded?

    Tricida was founded in 2013.

  • Where is Tricida headquartered?

    Tricida is headquartered in Sacramento, CA.

  • What is the size of Tricida?

    Tricida has 55 total employees.

  • What industry is Tricida in?

    Tricida’s primary industry is Drug Discovery.

  • Is Tricida a private or public company?

    Tricida is a Public company.

  • What is Tricida’s stock symbol?

    The ticker symbol for Tricida is 1T7.

  • What is the current stock price of Tricida?

    As of 23-Jan-2023 the stock price of Tricida is $0.10.

  • What is the current market cap of Tricida?

    The current market capitalization of Tricida is $6.27M.

  • Who are Tricida’s competitors?

    Nascent Biotech, Akebia Therapeutics, Resverlogix, Esperion Therapeutics, and Ayala Pharmaceuticals are some of the 33 competitors of Tricida.

  • What is Tricida’s annual earnings per share (EPS)?

    Tricida’s EPS for 12 months was -$2.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process